Nasdaq:SEER
Seer, Inc.
A clinical-stage biotech innovator engineering intelligent artificial pancreas platforms for Type 1 diabetes management.
Key Metrics
Investment Thesis
Bull Case
Seer represents a high-risk, high-reward opportunity for investors seeking exposure to the rapidly growing artificial pancreas market which is projected to reach billions in value within the next decade. If the company successfully validates its technology or secures major strategic partnerships, the potential upside could be exponential given the current lack of commercial revenue and large cash reserves of $40.8M. The proprietary nature of the AI algorithms creates a defensible position that could disrupt the traditional insulin pump market dominated by legacy players.
Bear Case
The company's financial health is precarious with a net loss of $86.6M in 2024 and operating cash flow from continuing operations turning negative at -$46.1M, raising serious concerns about runway sustainability without external capital injection. Revenue contraction to $14.2M suggests potential product-market fit issues or intense competition eroding market share before a stable business model is established. With total liabilities of $39.0M and no current profitable operations, the stock carries significant dilution risk as the company likely needs to raise more equity to fund its ambitious development roadmap.
About Seer, Inc.
Seer is a pioneering biotechnology firm focused on developing next-generation artificial pancreas systems to treat Type 1 diabetes. The company leverages proprietary AI algorithms and continuous glucose monitoring technology to automate insulin delivery, serving patients globally who require advanced glycemic control solutions.
Analysis
Management Discussion
In 2024, Seer reported a net loss of $86.6M with revenue declining to $14.2M from $16.7M in the prior year, indicating challenges in maintaining sales momentum while expanding operations. The company continues to burn cash heavily through R&D expenditures of $50.6M and significant general and administrative costs totaling $56.6M, resulting in a substantial deficit in retained earnings of $392.4M.
Industry Overview
The global diabetes technology industry is experiencing a paradigm shift towards closed-loop systems that automatically regulate insulin delivery based on real-time glucose data. Traditional manufacturers are increasingly investing in software-defined hardware, while new entrants like Seer are disrupting the space with pure-play AI solutions. Regulatory bodies worldwide are tightening oversight on digital therapeutics, creating both hurdles for entry and opportunities for first-movers who can prove superior clinical outcomes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $15.5M | $16.7M | $14.2M |
| Cost of Revenue | $8.4M | $8.2M | $7.1M |
| Gross Profit | $7.1M | $8.5M | $7.1M |
| Operating Expenses | $104.3M | $112.0M | $107.2M |
| Operating Income | $-97.2M | $-103.5M | $-100.1M |
| R&D | $45.8M | $53.0M | $50.6M |
| G&A | $58.5M | $59.0M | $56.6M |
| Stock-Based Comp | $33.7M | $34.4M | $28.2M |
| D&A | — | — | $5.8M |
| Depreciation | $3.9M | $5.6M | $6.2M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $13.6M |
| Interest Expense | $0 | — | — |
| Interest Income | $4.6M | $17.8M | $16.7M |
| Pre-Tax Income | $-97.2M | $-103.5M | $-86.5M |
| Income Tax | $0 | $0 | $98.0K |
| Continuing Ops | $-97.2M | $-103.5M | $-86.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-93.0M | $-86.3M | $-86.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-93.0M | $-86.3M | $-86.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $435.0M | $330.5M | $253.3M |
| Cash & Equivalents | $53.2M | $32.5M | $40.8M |
| Accounts Receivable | $4.3M | — | — |
| Inventory | $4.6M | $4.5M | $7.4M |
| Other Current Assets | $372.8M | $293.5M | $205.1M |
| Long-Term Assets | $52.9M | $105.8M | $113.3M |
| PP&E (Net) | $19.4M | $22.2M | $18.6M |
| Operating Leases | $27.0M | $25.2M | $22.8M |
| Other LT Assets | $6.5M | $58.4M | $71.9M |
| Total Assets | $487.9M | $436.3M | $366.6M |
| Current Liabilities | $12.6M | $13.2M | $15.3M |
| Current Leases | $1.8M | $2.3M | $2.3M |
| Deferred Revenue | — | $206.0K | $408.0K |
| Other Current Liab | $2.4M | $1.5M | $4.7M |
| Long-Term Liabilities | $28.4M | $26.1M | $23.7M |
| LT Operating Leases | $28.0M | $26.0M | $23.7M |
| Other LT Liab | $320.0K | $179.0K | $48.0K |
| Total Liabilities | $40.9M | $39.4M | $39.0M |
| Shareholders' Equity | $447.0M | $396.9M | $327.6M |
| Paid-In Capital | $667.7M | $702.9M | $719.8M |
| Retained Earnings | $-219.5M | $-305.8M | $-392.4M |
| AOCI | $-1.3M | $-192.0K | $136.0K |
| Total L&E | $487.9M | $436.3M | $366.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-93.0M | $-86.3M | $-86.6M |
| Non-Cash Adjustments | $28.5M | $25.2M | $34.7M |
| Working Capital Changes | $3.7M | $2.0M | $5.8M |
| Cash from Operations | $-60.8M | $-59.1M | $-46.1M |
| Capital Expenditures | $10.3M | $7.3M | $3.6M |
| Cash from Investing | $-122.7M | $37.9M | $65.9M |
| Share Buybacks | $20.0K | $13.0K | $0 |
| Cash from Financing | $3.9M | $452.0K | $-11.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-179.6M | $-20.7M | $8.3M |
| Beginning Cash | $233.3M | $53.7M | $33.0M |
| Ending Cash | $53.7M | $33.0M | $41.3M |
Frequently Asked Questions
How does Seer, Inc. make money?
The company's revenue is derived primarily from sales of its proprietary artificial pancreas software and associated medical devices, supplemented by licensing agreements and potential collaborations with healthcare providers or technology partners within the broader digital health ecosystem.
What are the main risks for SEER?
As a clinical-stage biotechnology company with no current product sales generating profit, the firm faces significant cash burn risks and dependence on successful future commercialization or strategic partnerships. The highly competitive diabetes technology landscape includes established giants with deep pockets, creating substantial market entry barriers. Regulatory approval processes for medical devices and software as a medical device can be lengthy and costly, delaying revenue generation. Patient adoption rates and reimbursement policies by insurance providers remain uncertain variables that could impact long-term viability.
What is SEER's competitive advantage?
Seer possesses a robust intellectual property portfolio protecting its unique AI-driven control algorithms for insulin dosing. The company benefits from a highly specialized team of engineers and clinicians capable of rapidly iterating on software improvements. Its platform architecture allows for seamless integration with various third-party continuous glucose monitoring sensors, reducing entry barriers for patients.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.